Sign Up For Additional Information

Conference Cochairs

Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, Texas (AACR)
Tim F. Greten, National Cancer Institute, Bethesda, Maryland (NCI)
E.G. Elisabeth de Vries, University Medical Centre Gronigen, Gronigen, Netherlands (EORTC)

Hosted by the American Association for Cancer Research, the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer, the 2023 Molecular Targets and Cancer Therapeutics conference will return to the Hynes Convention Center in Boston. This program attracts 1,500-2,500 academics, scientists, and pharmaceutical industry representatives from across the globe to discuss innovations in drug development, target selection, the impact of new discoveries in cellular and molecular biology, and early clinical trials. Innovative, targeted therapeutics are discovered through the rapid advances in our understanding of the molecular basis of cancer. Continued clinical progress in cancer treatments is accomplished through the conduct of translational research projects, efficient new drug development, and the execution of large, prospective, randomized, multicenter cancer clinical trials. This requires a joint and global approach to exchange information early in the development process.

Organizing Committee Cochairs

Philip D. Greenberg, Fred Hutchinson Cancer Center, Seattle, Washington (AACR)
James H. Doroshow, National Cancer Institute, Bethesda, Maryland (NCI)
Denis A. Lacombe, European Organisation for Research and Treatment of Cancer, Brussels, Belgium (EORTC)

scientific Committee members

Christina M. Annunziata, National Cancer Institute, Bethesda, Maryland
Rosemarie Aurigemma, National Cancer Institute, Bethesda, Maryland
Udai Banerji, The Institute of Cancer Research, The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom
Bristi Basu, Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
Johanna Bendell, Roche, Basel, Switzerland
Alice P. Chen, National Cancer Institute, Bethesda, Maryland
Deborah E. Citrin, National Cancer Institute, Bethesda, Maryland
Giuseppe Curigliano, University of Milano, European Institute of Oncology, Milano, Italy
Ibiayi Dagogo-Jack, Massachusetts General Hospital Cancer Center, Boston, Massachusetts
E.G. Elisabeth de Vries, University Medical Centre Gronigen, Gronigen, Netherlands
James H. Doroshow, National Cancer Institute, Bethesda, Maryland
Elena Garralda, Vall d’Hebron Research Institute, Barcelona, Spain
Ignacio Garrido-Laguna, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah
Adrian L. Gill, Revolution Medicines, Redwood City, California
Lyndsay N. Harris, National Cancer Institute, Bethesda, Maryland
Timothy Heffernan, The University of Texas MD Anderson Cancer Center, Houston, Texas
Thomas U. Helleday, Karolinska Institutet, Stockholm, Sweden
Matthew D. Hellman, AstraZeneca Oncology, New York, New York
David Hyman, Loxo Oncology at Lilly, Stamford, Connecticut
Seock Ah Im, Seoul National University, Seoul, Korea
S. Percy Ivy, National Cancer Institute, Bethesda, Maryand
Filip Janku, Monte Rosa Therapeutics, Boston, Massachusetts
Patricia M. LoRusso, Yale Cancer Center, New Haven, Connecticut
Jason J. Luke, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Ignacio Melero, Clinica Universidad de Navarra, Pamplona, Spain
Gordon B. Mills, OHSU Knight Cancer Institute, Portland, Oregon
Victor Moreno, START Madrid, Madrid, Spain
Jeffrey A. Moscow, National Cancer Institute, Bethesda, Maryland
Natalie Ngoi, National University Cancer Institute Singapore, Singapore, Singapore
Ralph E.  Parchment, NCI Frederick, Frederick, Maryland
Sophie C. Postel-Vinay, Institut Gustave Roussy, Paris, France
Jordi Rodón, The University of Texas MD Anderson Cancer Center, Houston, Texas
Mark Roschewski, National Cancer Institute, Bethesda, Maryland
Eytan Ruppin, National Cancer Institute, Bethesda, Maryland
Kurt A. Schalper, Yale Cancer Center, New Haven, Connecticut
Patrick Schoffski, Catholic University of Leuven, Leuven Cancer Institute, Leuven, Belgium
Alison Schram, Memorial Sloan Kettering Cancer Center, New York, New York
Lesley Seymour, Queens University, Kingston, Ontario, Canada
Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, Massachusetts
Fiona Simpkins, Perelman School of Medicine University of Pennsylvania, Philadelphia, Pennsylvania
Jean-Charles Soria, Amgen Oncology, Thousand Oaks, California
Ramaprasad Srinivasan, National Cancer Institute, Bethesda, Maryland
Stefan N. Symeonides, University of Edinburgh, Edinburgh, Scotland
Beverly A. Teicher, National Cancer Institute, Bethesda, Maryland
Anish Thomas, National Cancer Institute, Bethesda, Maryland
Samra Turajlic, The Franics Crick Institute, London, England
Eric Van Cutsem, University Hospitals Gasthuisberg / Leuven & KULeuven, Leuven, Belgium
Mike Waring, Northern Institute for Cancer Research, Newcastle upon Tyne, England
Brigitte C. Widemann, National Cancer Institute, Bethesda, Maryland
Noboru Yamamoto, National Cancer Center Hospital, Tokyo, Japan